Biological Activity
MHY1485 is a cell-permeable mTOR activator. MHY1485 has an inhibitory effect on the autophagic process by inhibition of fusion between autophagosomes and lysosomes.
In Vitro
MHY1485 induces mTOR activity, which is another regulator of autophagy. MHY1485 markedly increases the LC3II/LC3I ratio dose-dependently and time-dependently[1]. An mTOR activator MHY1485 stimulates mTOR, S6K1 and rpS6 phosphorylation. Treatment with MHY1485 increases phospho-mTOR levels without affecting total mTOR content. MHY1485 treatment also increases the phosphorylation of downstream S6K1 and rpS6 proteins without affecting total S6K1 and rpS6 levels[2]. An mTOR activator, MHY1485, also abolishes the inhibitory effect of liraglutide on osteoblastic differentiation, and results in p-mTOR and TGF-β downregulation, but does not attenuate the liraglutide-induced increase in p-AMPK protein expression levels. Co-treatment with 4 nM Liraglutide and 1 µM MHY1485, an mTOR activator, results in protein expression levels of Alp, OC, p-mTOR and TGF-β and matrix mineralization comparable to those of positive control cells cells[3]. MHY1485 treatment increases ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation, which are downstream targets of mTOR complex 1 (mTORC1), but decreases phosphorylation of Akt on mTOR complex 2 (mTORC2) target site serine 473[4].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.